Users' Guides to the Medical Literature
- 11 June 1997
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 277 (22) , 1802-1806
- https://doi.org/10.1001/jama.1997.03540460066034
Abstract
CLINICAL SCENARIO You recall from the first of our 2 articles1concerning economic analysis of clinical practice that your chief of medicine has asked you to review relevant economic evidence from the literature and report to the hospital's pharmacy and therapeutics committee, which is trying to decide on formulary guidelines for the use of streptokinase and tissuetype plasminogen activator (t-PA) in the treatment of acute myocardial infarction (AMI). Your literature search identified 2 recent key cost-effectiveness studies: an analysis of economic data collected prospectively as part of the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) trial2of streptokinase vs t-PA by Mark et al,3and a decision-analytic model by Kalish et al.4In the first article of this 2-part series we showed you how to evaluate the validity of the different economic appraisal study methods. In this article, we willKeywords
This publication has 7 references indexed in Scilit:
- Cost Effectiveness of Tissue Plasminogen ActivatorNew England Journal of Medicine, 1995
- A Response to “Holding GUSTO Up to the Light”Annals of Internal Medicine, 1994
- In Search of Power and Significance: Issues in the Design and Analysis of Stochastic Cost-Effectiveness Studies in Health CareMedical Care, 1994
- On the decision rules of cost-effectiveness analysisJournal of Health Economics, 1993
- An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial InfarctionNew England Journal of Medicine, 1993
- Cost-effectiveness league tables: More harm than good?Social Science & Medicine, 1993
- Utilities and Quality-Adjusted Life YearsInternational Journal of Technology Assessment in Health Care, 1989